Triggering CD40 on endothelial cells contributes to tumor growth

Claudia Chiodoni, Manuela Iezzi, Cristiana Guiducci, Sabina Sangaletti, Isabella Alessandrini, Chiara Ratti, Francesca Tiboni, Piero Musiani, D. Neil Granger, Mario P. Colombo

Research output: Contribution to journalArticle

Abstract

Inflammatory cells can either promote or inhibit tumor growth. Here we studied whether CD40, a key molecule for adaptive immune response, has any role in mammary carcinogenesis of BALB/NeuT transgenic tumor-prone mice. We transferred the HER2/neu oncogene into CD40-null background to obtain the CD40-KO/NeuT strain. CD40-KO/NeuT mice showed delayed tumor onset and reduced tumor multiplicity. BM (BM) transplantation experiments excluded a role of BM-derived cells in the reduced tumorigenicity associated with CD40 deficiency. Rather, CD40 expressed by endothelial cells (ECs) takes part to the angiogenic process. Accordingly, large vessels, well organized around the tumor lobular structures, characterize BALB/NeuT tumors, whereas tiny numerous vessels with scarce extracellular matrix are dispersed in the parenchyma of poorly organized CD40-KO/NeuT tumors. Activated platelets, which may interact with and activate ECs, are a possible source of CD40L. Their localization within tumor vessels prompted the idea of treating BALB/NeuT and CD40-KO/NeuT mice chronically with the anti-platelet drug clopidogrel, known to inhibit platelet CD40L expression. Treatment of BALB/NeuT mice reduced tumor growth to a level similar to CD40-deficient mice, whereas CD40-KO/NeuT mice treated or not showed the same attenuated tumor outgrowth, indicating that activated platelets are the likely source of CD40L in this model. Collectively, these data point to a participation of CD40/CD40L in the angiogenic processes associated with mammary carcinogenesis of BALB/NeuT mice. JEM

Original languageEnglish
Pages (from-to)2441-2450
Number of pages10
JournalJournal of Experimental Medicine
Volume203
Issue number11
DOIs
Publication statusPublished - Oct 2006

Fingerprint

Endothelial Cells
Growth
CD40 Ligand
Neoplasms
Blood Platelets
clopidogrel
Carcinogenesis
Breast
Adaptive Immunity
Oncogenes
Extracellular Matrix
Transplantation
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology

Cite this

Triggering CD40 on endothelial cells contributes to tumor growth. / Chiodoni, Claudia; Iezzi, Manuela; Guiducci, Cristiana; Sangaletti, Sabina; Alessandrini, Isabella; Ratti, Chiara; Tiboni, Francesca; Musiani, Piero; Granger, D. Neil; Colombo, Mario P.

In: Journal of Experimental Medicine, Vol. 203, No. 11, 10.2006, p. 2441-2450.

Research output: Contribution to journalArticle

Chiodoni, C, Iezzi, M, Guiducci, C, Sangaletti, S, Alessandrini, I, Ratti, C, Tiboni, F, Musiani, P, Granger, DN & Colombo, MP 2006, 'Triggering CD40 on endothelial cells contributes to tumor growth', Journal of Experimental Medicine, vol. 203, no. 11, pp. 2441-2450. https://doi.org/10.1084/jem.20060844
Chiodoni C, Iezzi M, Guiducci C, Sangaletti S, Alessandrini I, Ratti C et al. Triggering CD40 on endothelial cells contributes to tumor growth. Journal of Experimental Medicine. 2006 Oct;203(11):2441-2450. https://doi.org/10.1084/jem.20060844
Chiodoni, Claudia ; Iezzi, Manuela ; Guiducci, Cristiana ; Sangaletti, Sabina ; Alessandrini, Isabella ; Ratti, Chiara ; Tiboni, Francesca ; Musiani, Piero ; Granger, D. Neil ; Colombo, Mario P. / Triggering CD40 on endothelial cells contributes to tumor growth. In: Journal of Experimental Medicine. 2006 ; Vol. 203, No. 11. pp. 2441-2450.
@article{6c368844eb774de5804d3f5dc28647d1,
title = "Triggering CD40 on endothelial cells contributes to tumor growth",
abstract = "Inflammatory cells can either promote or inhibit tumor growth. Here we studied whether CD40, a key molecule for adaptive immune response, has any role in mammary carcinogenesis of BALB/NeuT transgenic tumor-prone mice. We transferred the HER2/neu oncogene into CD40-null background to obtain the CD40-KO/NeuT strain. CD40-KO/NeuT mice showed delayed tumor onset and reduced tumor multiplicity. BM (BM) transplantation experiments excluded a role of BM-derived cells in the reduced tumorigenicity associated with CD40 deficiency. Rather, CD40 expressed by endothelial cells (ECs) takes part to the angiogenic process. Accordingly, large vessels, well organized around the tumor lobular structures, characterize BALB/NeuT tumors, whereas tiny numerous vessels with scarce extracellular matrix are dispersed in the parenchyma of poorly organized CD40-KO/NeuT tumors. Activated platelets, which may interact with and activate ECs, are a possible source of CD40L. Their localization within tumor vessels prompted the idea of treating BALB/NeuT and CD40-KO/NeuT mice chronically with the anti-platelet drug clopidogrel, known to inhibit platelet CD40L expression. Treatment of BALB/NeuT mice reduced tumor growth to a level similar to CD40-deficient mice, whereas CD40-KO/NeuT mice treated or not showed the same attenuated tumor outgrowth, indicating that activated platelets are the likely source of CD40L in this model. Collectively, these data point to a participation of CD40/CD40L in the angiogenic processes associated with mammary carcinogenesis of BALB/NeuT mice. JEM",
author = "Claudia Chiodoni and Manuela Iezzi and Cristiana Guiducci and Sabina Sangaletti and Isabella Alessandrini and Chiara Ratti and Francesca Tiboni and Piero Musiani and Granger, {D. Neil} and Colombo, {Mario P.}",
year = "2006",
month = "10",
doi = "10.1084/jem.20060844",
language = "English",
volume = "203",
pages = "2441--2450",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "11",

}

TY - JOUR

T1 - Triggering CD40 on endothelial cells contributes to tumor growth

AU - Chiodoni, Claudia

AU - Iezzi, Manuela

AU - Guiducci, Cristiana

AU - Sangaletti, Sabina

AU - Alessandrini, Isabella

AU - Ratti, Chiara

AU - Tiboni, Francesca

AU - Musiani, Piero

AU - Granger, D. Neil

AU - Colombo, Mario P.

PY - 2006/10

Y1 - 2006/10

N2 - Inflammatory cells can either promote or inhibit tumor growth. Here we studied whether CD40, a key molecule for adaptive immune response, has any role in mammary carcinogenesis of BALB/NeuT transgenic tumor-prone mice. We transferred the HER2/neu oncogene into CD40-null background to obtain the CD40-KO/NeuT strain. CD40-KO/NeuT mice showed delayed tumor onset and reduced tumor multiplicity. BM (BM) transplantation experiments excluded a role of BM-derived cells in the reduced tumorigenicity associated with CD40 deficiency. Rather, CD40 expressed by endothelial cells (ECs) takes part to the angiogenic process. Accordingly, large vessels, well organized around the tumor lobular structures, characterize BALB/NeuT tumors, whereas tiny numerous vessels with scarce extracellular matrix are dispersed in the parenchyma of poorly organized CD40-KO/NeuT tumors. Activated platelets, which may interact with and activate ECs, are a possible source of CD40L. Their localization within tumor vessels prompted the idea of treating BALB/NeuT and CD40-KO/NeuT mice chronically with the anti-platelet drug clopidogrel, known to inhibit platelet CD40L expression. Treatment of BALB/NeuT mice reduced tumor growth to a level similar to CD40-deficient mice, whereas CD40-KO/NeuT mice treated or not showed the same attenuated tumor outgrowth, indicating that activated platelets are the likely source of CD40L in this model. Collectively, these data point to a participation of CD40/CD40L in the angiogenic processes associated with mammary carcinogenesis of BALB/NeuT mice. JEM

AB - Inflammatory cells can either promote or inhibit tumor growth. Here we studied whether CD40, a key molecule for adaptive immune response, has any role in mammary carcinogenesis of BALB/NeuT transgenic tumor-prone mice. We transferred the HER2/neu oncogene into CD40-null background to obtain the CD40-KO/NeuT strain. CD40-KO/NeuT mice showed delayed tumor onset and reduced tumor multiplicity. BM (BM) transplantation experiments excluded a role of BM-derived cells in the reduced tumorigenicity associated with CD40 deficiency. Rather, CD40 expressed by endothelial cells (ECs) takes part to the angiogenic process. Accordingly, large vessels, well organized around the tumor lobular structures, characterize BALB/NeuT tumors, whereas tiny numerous vessels with scarce extracellular matrix are dispersed in the parenchyma of poorly organized CD40-KO/NeuT tumors. Activated platelets, which may interact with and activate ECs, are a possible source of CD40L. Their localization within tumor vessels prompted the idea of treating BALB/NeuT and CD40-KO/NeuT mice chronically with the anti-platelet drug clopidogrel, known to inhibit platelet CD40L expression. Treatment of BALB/NeuT mice reduced tumor growth to a level similar to CD40-deficient mice, whereas CD40-KO/NeuT mice treated or not showed the same attenuated tumor outgrowth, indicating that activated platelets are the likely source of CD40L in this model. Collectively, these data point to a participation of CD40/CD40L in the angiogenic processes associated with mammary carcinogenesis of BALB/NeuT mice. JEM

UR - http://www.scopus.com/inward/record.url?scp=33750531271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750531271&partnerID=8YFLogxK

U2 - 10.1084/jem.20060844

DO - 10.1084/jem.20060844

M3 - Article

C2 - 17043144

AN - SCOPUS:33750531271

VL - 203

SP - 2441

EP - 2450

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 11

ER -